Send to

Choose Destination
PLoS One. 2014 Oct 10;9(10):e109123. doi: 10.1371/journal.pone.0109123. eCollection 2014.

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

Author information

Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan.
Shunkaikai, Inoue Hospital, Nagasaki, Japan.
Department of Gastroenterology, Jichi Medical University, Saitama Medical Center, Omiya, Japan.
Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan.
Center for Preventive Medicine, NTT Medical Center Tokyo, Tokyo, Japan.
National Center for Global Health and Medicine, Tokyo, Japan.
Center for Animal Resources and Development, Kumamoto University, Kumamoto, Japan.
Laboratory of Molecular Biomedicine for Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan; Max Planck-The University of Tokyo Center for Integrative Inflammology, Tokyo, Japan; CREST, Japan Science and Technology Agency, Tokyo, Japan.



Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC.


Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99 ± 1.8 µg/ml in men and 6.06 ± 2.1 µg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis.


AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center